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Coronaviruses have the potential to cause severe 
transmissible human disease, as demonstrated by the 
severe acute respiratory syndrome (SARS) outbreak of 
2003. We describe here the clinical and virological fea-
tures of a novel coronavirus infection causing severe 
respiratory illness in a patient transferred to London, 
United Kingdom, from the Gulf region of the Middle 
East.
Introduction
Coronaviruses are recognised causes of mild respira-
tory tract infections in humans, first identified in the 
1960s [1]. These large RNA viruses affect a wide range 
of animals including domestic and companion animals 
and bats [2]. Limited surveillance data show that bats 
host the greatest diversity of coronaviruses, varying by 
region and species [3], suggesting that they may be the 
natural reservoir. 
The severe acute respiratory syndrome (SARS) out-
break of 2003 – affecting over 8,000 people across 
three continents with a case fatality ratio of about 10% 
[4] – indicates the potential of an animal coronavirus to 
jump species and transmit from person to person caus-
ing severe illness. This experience has raised aware-
ness of the potential threat from zoonotic coronaviral 
infections and the need to adopt strict infection con-
trol measures when such cases are found, especially in 
healthcare settings. We describe here the clinical fea-
tures and diagnostic detection of a novel coronavirus 
infection in a severely ill adult transferred to London, 
United Kingdom, from the Gulf region of the Middle 
East for medical care. 
Case history
On 14 September 2012, the United Kingdom Health 
Protection Agency (HPA) Imported Fever Service was 
notified of a case of unexplained severe respiratory 
illness in a London intensive care unit. The patient had 
recently transferred from Qatar and had a history of 
travel to Saudi Arabia. 
He was a previously well 49 year-old man who devel-
oped a mild undiagnosed respiratory illness while 
visiting Saudi Arabia during August 2012, which fully 
resolved.  He subsequently presented to a physician 
in Qatar on 3 September, with cough, myalgia and 
arthralgia, and was prescribed oral antibiotics.  Five 
days later, he was admitted to a Qatari hospital with 
fever (38.4 °C) and hypoxia, with oxygen saturation 
of 91% on room air. A chest X-ray showed bilateral 
lower zone consolidation.  He was treated with ceftri-
axone, azithromycin and oseltamivir. After 48 hours, 
he required intubation and ventilation and was trans-
ferred by air ambulance to London. During transfer, he 
was clinically unstable, requiring manual ventilation.
On admission to intensive care in London, he remained 
severely hypoxic, achieving an arterial PaO2 of 6.5 kPA 
(normal range: 11–13 kPA) on 100% oxygen with opti-
mised pressure ventilation, and required low-dose 
norepinephrine to maintain blood pressure.  His white 
blood cell count was 9.1 x 109/L (normal range: 4–11 x 
109/L), C-reactive protein 350 mg/L (normal range: 0–10 
mg/L) and creatinine 353 μmol/L (normal range: 53–97 
μmol/L), with normal liver function and coagulation. 
He was treated with corticosteroids and broad-spec-
trum antibiotics, initially meropenem, clarithromycin 
and teicoplanin. Colistin and liposomal amphotericin B 
were subsequently added. 
His condition deteriorated between 11 and 20 
September, with progressive hypoxia.  His C-reactive 
protein level peaked at 440 mg/L and procalcitonin at 
68 ng/ml (normal level:  <0.5 ng/ml). His renal func-
tion worsened and haemofiltration was initiated on 14 
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September. He was transferred to a specialist intensive 
care unit and on 20 September (day 17 of illness), extra-
corporeal membrane oxygenation (ECMO) was started. 
As of 2 October, he remains stable but fully dependent 
on ECMO after 13 days (day 30 of illness).
Diagnostic approach 
Microbiological diagnostics in Qatar and London were 
used to look initially for common viral and bacterial 
causes of severe respiratory illness and subsequently 
for pathogens endemic in the Middle East (Table 1). By 
mid-September, the syndrome was considered most 
compatible with viral pneumonia. Upper and lower res-
piratory tract samples were sent to the HPA Respiratory 
Virus Unit for extended influenza testing; all were neg-
ative. On 20 September, a ProMED report described 
a novel human coronavirus recovered from an adult 
male Saudi Arabian who died in June 2012 following 
acute respiratory illness, pneumonia and renal failure 
[5]. The Erasmus Medical Center (the Netherlands) had 
sequenced the virus and identified it as a previously 
undescribed coronavirus, related to known bat corona-
viruses. Given that the patient described in our report 
had travelled to Saudi Arabia, HPA, in consultation with 
local clinicians, decided to investigate samples from 
the patient for the presence of the novel coronavirus.
Detection of a novel coronavirus
We used real-time PCR on upper (nose and throat 
swabs) and lower respiratory tract samples (sputum 
and tracheal aspirates) to test for a range of coronavi-
ruses: OC43, 229E, NL63 and SARS-CoV. We also used 
Source Sample
Date of investigation (September 2012)
9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25
Qatar Broncho-alveolar lavage
London:  
ICU
Combined nose and throat swab
Local bacterial/viral testinga
Imported fever panel  
(blood/serum/urine/throat swab)b
Sputum
Nose swab
Throat swab
Tracheal aspirate
London: 
specialist 
ICU
Broncho-alveolar lavagec
Cerebrospinal fluid
Blood (EDTA/serum)
Stool
EDTA: ethylenediaminetetraacetic acid; ICU: intensive care unit; PCR: polymerase chain reaction.
Red = coronavirus detected (pan-coronavirus assay and real-time PCR assay for UpE and ORF1b (specific for novel coronavirus)
Green = no pathogens detected, including testing by pan-coronavirus assay
Blue = negative for all pathogens (not tested by pan-coronavirus assay)
a  Included multiple blood and sputum cultures; urinalysis; atypical pneumonia screen; blood-borne virus screen; Epstein–Barr virus, 
cytomegalovirus, and varicella zoster virus; respiratory virus screen; mycobacterial respiratory screen; and tracheostomy site culture.
b  Included dengue virus; West Nile virus; chikungunya virus; hantavirus; Sindbis virus; Rift Valley fever virus; sandfly viruses; Rickettsiae; 
Coxiella burnettii; Burkholderia mallei and B. pseudomallei.
c  Negative for respiratory bacterial culture and mycobacterial stain and respiratory Influenza A/B, parainfluenza 1-4, RSV A/B, human 
metapneumovirus, enterovirus, rhinovirus, adenovirus, human bocavirus, and the human coronaviruses (NL63, 229E, OC43, HKU1).
Table 1
Microbiological investigations performed on London patient with novel coronavirus infection, September 2012
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a block-based pan-coronavirus PCR with degenerate 
primers targeted to the conserved RNA-dependent RNA 
polymerase (RdRp Pol) gene that detects all coronavi-
ruses known to infect humans and a range of animal 
coronaviruses [6]. The pan-coronavirus assay yielded a 
band of the correct size in lower respiratory tract sam-
ples, but the assays for OC43, 229E, NL63 and SARS-
coronaviruses were negative. Sanger sequencing of 
the pan-coronavirus PCR product (a 251 base pair frag-
ment encompassing nucleotides 104–354 of the NSP12 
gene) yielded a sequence that on BLAST analysis gave 
genetic identity of 81% to bat coronavirus/133/2005 
(GenBank accession number DQ648794.1) and 75% 
identity to porcine haemagglutinating encephalomy-
elitis virus strain VW572 (GenBank accession number 
DQ011855.1) The sequence identified is available on 
the HPA website [7].  In response to this identification, 
a new set of real-time RT PCR assays were developed 
[8]. The results of these assays tested on novel corona-
virus tissue culture material and clinical samples from 
this confirmed case are shown in Table 2. 
On the basis of the sequence obtained, a maximum 
likelihood tree (Figure) showed that the virus belongs 
to the genus Betacoronavirus, with closest relation-
ships to bat coronaviruses HKU4 and HKU5.  Viruses 
that share more than 90% sequence identity in the 
conserved replicase domain are considered to belong 
to the same species by the International Committee on 
Taxonomy of Viruses (ICTV).  Our sequence compari-
sons suggested that the virus nucleic acid fragment 
identified is derived from a novel coronavirus that is 
distinct from all coronaviruses described to date.
A total of 13 close contacts of the index case were iden-
tified who had developed mild self-limiting respira-
tory illnesses since exposure to the case [8].  Ten of 
these have had nose and throat swabs tested by pan-
coronavirus assay and the novel coronavirus was not 
detected.  
Discussion
Ascribing viral taxonomy on the basis of a small seg-
ment of sequence representing less than 1% of a viral 
genome is highly presumptive.  However, the replicase 
genes are extremely conserved within coronaviruses, 
and the gene targeted by the pan-coronavirus assay is 
highly correlated with taxonomic classification based 
on the whole genome [9], confirming the choice of 
assay and the validity of the phylogeny (Figure).  Final 
allocation of taxonomy and nearest neighbour related-
ness will require more extensive sequence obtained 
either through genomic analysis of virus isolates cul-
tured from the available clinical material, or more 
extensive partial genome sequence derived directly 
from clinical material if virus isolation is not possible.
While most coronaviral infections of humans cause mild 
illness, zoonotic transmission of animal coronaviruses 
such as SARS-CoV can cause severe illness and death. 
Preliminary data sharing (Ron Fouchier, personal com-
munication, 23 September 2012) indicates 99.5% iden-
tity over the region of the replicase compared with the 
virus isolated from the patient in Saudi Arabia and 
described in ProMED. This is confirmed by the publica-
tion of the whole genome sequence (GenBank acces-
sion number JX869059.1). On the basis of the clinical 
and virological features, we believe that the fragment 
Sample/isolate
E Gene ORF 1b Gene
Rotorgene (Ct) ABI Taqman (Ct) Rotorgene (Ct) ABI Taqman (Ct)
 Novel coronavirus isolated in the Netherlands (patient from Saudi Arabia) reported to ProMED
Cultured virus  (approximate 
titre 106/ml) 18.9 17.5 22.7 21.9
Samples from confirmed case in London
Combined nose  
and  throat swab  
13/9/ 2012
30.5 28.8 35.6 35.4
Sputum 
 
17/12/2012
28.3 26.6 32.8 31.7
Deep tracheal  
aspirate
19/12/2012
26.2 24.9 31.4 30.0
Ct: cycle threshold; PCR: polymerase chain reaction.
Results of specific real-time PCR assays [10] directed towards the upstream E gene (UpE) and the ORF 1b region of the new coronavirus tested 
against cultured virus from the patient who died in Saudi Arabia, and clinical material from the confirmed case of novel coronavirus in 
London.
Table 2
Real-time PCR results of coronavirus samples, September 2012
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of coronaviral sequence we have recovered represents 
a novel human coronavirus causing a severe respira-
tory illness.  
The rapid development of sensitive and specific 
molecular diagnostics for new organisms is facilitated 
by sharing information and data between laborato-
ries with different capabilities or reagents. The initial 
molecular approaches used in this case were part of a 
broad screening approach based on experience gained 
during the response to SARS. The development of spe-
cific diagnostics for the novel coronavirus will improve 
sensitivity and enable rapid exclusion or identification 
of potential clinical cases. 
The origin for this novel virus is unknown. 
Epidemiological human and animal investigations in 
the region of origin are required to distinguish between 
an animal reservoir that either directly or indirectly 
transmits the virus occasionally to humans, and a pre-
viously unrecognised endemic infection of humans that 
causes severe outcomes in a few of those infected. 
Distinguishing between these possibilities will require 
wider application of more specific and sensitive molec-
ular assays for coronaviruses, and greater awareness 
of the possible presence of coronaviruses in human 
acute severe respiratory illness. Extensive serological 
testing of potentially exposed human populations and 
contacts will be a key indicator of the extent of disease 
due to novel coronaviruses.
Figure 
Phylogenetic relationships of partial sequences from the polymerase gene (nsp12) of the coronavirus sequence obtained at 
the Health Protection Agency, together with representative coronaviruses from different groups
The sequence obtained at the Health Protection Agency has been tentatively named as London1_novel CoV 2012. The phylogenetic tree was 
constructed with fastTree software, using the maximum-likelihood method with general time-reversible model of nucleotide substitution. 
Bootstrap values were obtained with 1,000 replicates. Coronavirus groups are shown on the right hand side of the tree, with 1, 2 and 3 
corresponding to Alpha, Beta and Gammacoronaviruses respectively. 
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